Tabalumab
Tabalumab (LY 2127399) is an anti-B-cell activating factor (BAFF) human monoclonal antibody designed for the treatment of autoimmune diseases and B cell malignancies.[1][2] Tabalumab was developed by Eli Lilly and Company.
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | BAFF |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6518H10008N1724O2032S38 |
| Molar mass | 146252.08 g·mol−1 |
  (what is this?) (verify) | |
A phase III clinical trial for rheumatoid arthritis was halted in Feb 2013.[3] In September 2014, a second phase III trial focussing on treating systemic lupus erythematosus, was terminated early as the study failed to meet its primary endpoint.[4]
References
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Tabalumab" (PDF). American Medical Association.
- http://www.lillyoncologypipeline.com/Pages/baff-antibody.aspx
- http://lilly.mediaroom.com/index.php?s=9042&item=136985
- http://www.genengnews.com/gen-news-highlights/lilly-halts-tabalumab-development-for-lupus/81250423/
Now dropped by Lilly due to lack of efficacy.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.